Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02030366
Other study ID # 9994-12-SMC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 1, 2015
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Sheba Medical Center
Contact Jacob Zauberman, MD
Phone 97235302440
Email Jacob.Zauberman@sheba.health.gov.il
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Traumatic Brain Injury (TBI) is a common injury in combat, terrorist attacks and sports such as football and hockey. Unnecessary delays in the diagnosis and treatment of brain damage in patients who can benefit from evacuation procedures can lead to worse brain injury, worse outcome and, sometimes, unnecessary death. However, there is no reliable and sensitive method for diagnosis of TBI severity in the field. In this study we will examine the feasibility of using this a multifocal chromatic pupillometer for monitoring TBI, by examining the pupillary response to multifocal chromatic stimuli in intracranial pressure (ICP)-monitored severe TBI patients. As control, normal subjects will be tested for pupillary responses using this device.


Description:

To examine the feasibility of using the multifocal chromatic pupillometer for monitoring TBI, the pupillary response to multifocal chromatic stimuli will be assessed in 20 healthy subjects and 20 ICP-monitored severe TBI patients. The portable pupillometer will be tested in 20 healthy volunteers. Their pupillary responses will be measured 3 times/day for 1 week. Pupillary response of 20 severe TBI patients will be evaluated as detailed below at the following time points: 1. At admittance to ICU, prior to insertion of ICP and CT scan 2. Prior to CT scans that are routinely performed at day 3 and 7 post injury 3. Routinely at the beginning of every medical personnel shift for 7 days (3 times a day). 4. With every change in ICP(more than 5 mmHg for more then 15 min) Data will be recorded and analyzed.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Healthy subjects - - Male or female patients, age between 18 and 70 years, inclusive - Informed written consent will be obtained from all participants. - Normal eye examination - Best-corrected visual acuity (BCVA) of 20/20 - Normal color vision test (Roth-28-hue test) - Written informed consent to participate in the study, - TBI-patients: - Male or female patients, age between 18 and 70 years, inclusive - Initiation of study before the insertion of the ICP monitor. - TBI diagnosed by history and clinical examination - Glasgow Coma Scale (GCS) score between 3 and 8, inclusive - Evidence of TBI confirmed by abnormalities consistent with trauma on CT scan upon admission (diffuse injury II-IV, evacuated and non-evacuated mass lesion, Marshall's CT Classification) - Indication for ICP monitoring - Written informed consent to participate in the study, signed by a family member and independent physician. Exclusion Criteria: - Healthy subjects - History of past or present ocular disease - Use of any topical or systemic medications that could adversely influence efferent pupil movements - TBI-patients - High levels of barbiturate medications as they abolish pupillary responsiveness - Coma suspected to be primarily due to other causes (e.g. alcohol) - Preexisting clinically significant disease or chronic condition that can be ascertained at the time of admission and could affect pupillary response or measurement (such as known retinal dystrophy disease, glaucoma or dense cataract.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Neurosurgery Department, Sheba Medical Center Tel Hashomer

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Skaat A, Sher I, Kolker A, Elyasiv S, Rosenfeld E, Mhajna M, Melamed S, Belkin M, Rotenstreich Y. Pupillometer-based objective chromatic perimetry in normal eyes and patients with retinal photoreceptor dystrophies. Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2761-70. doi: 10.1167/iovs.12-11127. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Pupillary response at 5 points of Visual field to blue and red light Pupillary response at 5 points of Visual field to blue and red light will be measured 3 times a day for a week for the health subjects. The TBI patients will be monitored for pupillary response:
At admittance to ICU, prior to insertion of ICP and CT scan
Prior to CT scans that are routinely performed at day 3 and 7 post injury
Routinely at the beginning of every medical personnel shift for 7 days (3 times a day).
With every change in ICP(more than 5 mmHg for more then 15 min)
7 days
Secondary Intra Cranial Pressure TBI patients only will be continuously monitored for Intra Cranial Pressure (ICP) 7 days